Market Place
Sourcing Support
MEI Pharma, after failed Infinity merger last year, to strategic alternatives
22 Jul 2024 //
FIERCE BIOTECH
Bankrupt Biotech`s Drug Shows Promise Against COVID-19 And MRSA
09 Jul 2024 //
FIERCE BIOTECH
Infinity files for bankruptcy after layoffs, scrapped merger with MEI Pharma
02 Oct 2023 //
ENDPTS
Infinity cuts 78% of staff, board members after MEI merger fails
26 Jul 2023 //
FIERCE BIOTECH
Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan
25 Jul 2023 //
BUSINESSWIRE
The Infinity-MEI merger saga ends in shareholders sinking deal
24 Jul 2023 //
FIERCE BIOTECH
Infinity Pharma Announces Stockholder Approval of Merger with MEI Pharma
14 Jul 2023 //
BUSINESSWIRE
MEI Pharma Provides Reminder to Shareholders to Vote FOR Merger With Infinity
11 Jul 2023 //
BUSINESSWIRE
Infinity Pharma Provides Information on MARIO-8 Study Evaluating Eganelisib
10 Jul 2023 //
BUSINESSWIRE
MEI Pharma Reminds Shareholders to Vote FOR Merger with Infinity Pharmaceuticals
07 Jul 2023 //
BUSINESSWIRE
ISS Recommends Infinity Pharma Stockholders Vote FOR the Merger with MEI
05 Jul 2023 //
BUSINESSWIRE
MEI Pharma Mails Letter to Shareholders Reiterating Value with Infinity
29 Jun 2023 //
BUSINESSWIRE
MEI and Infinity Host Webcast Providing Overview to Advance Oncology Candidates
15 Jun 2023 //
BUSINESSWIRE
MEI turns down ‘significantly undervalued’ takeover offer
01 Jun 2023 //
FIERCE BIOTECH
Infinity merger with MEI in doubt after surprise buyer makes bid
31 May 2023 //
FIERCE BIOTECH
Infinity Pharma Announces Two Upcoming Presentations on PI3K-? and Eganelisib
13 Apr 2023 //
BUSINESSWIRE
Infinity facing bankruptcy if MEI merger falls through
29 Mar 2023 //
FIERCE BIOTECH
Infinity Pharmaceuticals Reports Full Year 2022 Financial Results
28 Mar 2023 //
BUSINESSWIRE
Infinity Laboratories Names Hank Nowak Commercial Ops SVP
22 Mar 2023 //
CONTRACT PHARMA
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement
23 Feb 2023 //
BUSINESSWIRE
Infinity pools resources with MEI in cancer-focused merger
23 Feb 2023 //
FIERCE BIOTECH
Infinity to Participate in Piper Sandler 34th Annual Healthcare Conference
22 Nov 2022 //
BUSINESSWIRE
Infinity Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
BUSINESSWIRE
Infinity Announces the Date of Third Quarter 2022 Financial Results Conference
07 Nov 2022 //
BUSINESSWIRE
Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences
31 Aug 2022 //
BUSINESSWIRE
Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
BUSINESSWIRE
Infinity Pharma Announces Date of Its Second Quarter 2022 Financial Results
02 Aug 2022 //
BUSINESSWIRE
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Conference
17 May 2022 //
BUSINESSWIRE
Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results
03 May 2022 //
BUSINESSWIRE
Infinity Pharma to Report First Quarter 2022 Financial Results
26 Apr 2022 //
BUSINESSWIRE
Infinity Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Apr 2022 //
BUSINESSWIRE
Infinity Pharma to Present at 32nd Annual Oppenheimer Healthcare Conference
09 Mar 2022 //
BUSINESSWIRE
Infinity Pharma Outlines Eganelisib Development Strategy, Provides 2022 Guidance
05 Jan 2022 //
BUSINESSWIRE
Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 SABCS
10 Dec 2021 //
BUSINESSWIRE
Infinity to Present at Piper Sandler Virtual Healthcare Conference
22 Nov 2021 //
BUSINESSWIRE
Infinity Pharmaceuticals Appoints Robert Ilaria, Jr., M.D., as CFO
07 Sep 2021 //
BUSINESSWIRE
Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences
02 Sep 2021 //
BUSINESSWIRE
Infinity Pharmaceuticals Reports Inducement Grants to Chief Scientific Officer
04 Aug 2021 //
BUSINESSWIRE
Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results
27 Jul 2021 //
PR NEWSWIRE
Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial
27 Jul 2021 //
PR NEWSWIRE
Infinity Pharmaceuticals Hosting Webinar on MARIO-3 and MARIO-275 Phase 2 Trials
20 Jul 2021 //
BUSINESSWIRE
Infinity to Present at The Keystone Symposia Precision Oncology Meeting
14 Jun 2021 //
BUSINESSWIRE
Infinity Announces Closing of $92 Million Public Offering of Common Stock
18 Feb 2021 //
BUSINESSWIRE
Infinity Announces Pricing of $80 Million Public Offering of Common Stock
12 Feb 2021 //
BUSINESSWIRE
Infinity Announces Pricing of $80 Million Public Offering of Common Stock
12 Feb 2021 //
BUSINESSWIRE
Infinity Announces Pricing of $80 Million Public Offering of Common Stock
11 Feb 2021 //
BUSINESSWIRE
Infinity Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275
11 Feb 2021 //
BUSINESSWIRE
Infinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled
11 Feb 2021 //
BUSINESSWIRE
Infinity Pharmaceuticals Announces Conference Call for the ASCO Genitourinary
10 Feb 2021 //
PHARMIWEB
Infinity Announces Conference Call for the ASCO Genitourinary Cancers
10 Feb 2021 //
BUSINESSWIRE
Infinity Announces MARIO-275 Phase 2 Data in Patients with Advanced Urothelial
11 Jan 2021 //
YAHOO
Infinity Announces MARIO-275 Ph 2 Data in Patients with Urothelial Cancer
11 Jan 2021 //
BUSINESSWIRE
Infinity Provides Update for Eganelisib in Patients with Metastatic
06 Jan 2021 //
BUSINESSWIRE
Infinity Provides Update for Eganelisib in Patients with Metastatic Urothelial
05 Jan 2021 //
BUSINESSWIRE
Infinity Pharmaceuticals Presents Front-Line Triple Negative Breast Cancer
09 Dec 2020 //
BUSINESSWIRE
Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio
17 Nov 2020 //
BUSINESSWIRE
Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio
17 Nov 2020 //
YAHOO
Infinity Presents New MARIO-1 Phase 1/1b Clinical Data
09 Nov 2020 //
BIOSPACE
Infinity Presents New MARIO-1 Ph1/1b Clinical Data at The Society for (SITC)
09 Nov 2020 //
BUSINESSWIRE
Hematogenix Unites With 19 Organizations from the Healthcare Community
05 Oct 2020 //
PRNEWSWIRE
